Hepatitis B Virus X Protein Represses Mirna-148 a to Enhance Tumorigenesis
Xiaojie Xu,Zhongyi Fan,Lei Kang,Juqiang Han,Chengying Jiang,Xiaofei Zheng,Ziman Zhu,Huabo Jiao,Jing Lin,Kai Jiang,Lihua Ding,Hao Zhang,Long Cheng,Hanjiang Fu,Yi Song,Ying Jiang,Jiahong Liu,Rongfu Wang,Nan Du,Qinong Ye
DOI: https://doi.org/10.1172/jci64265
2013-01-01
Abstract:MicroRNAs (miRNAs) have been shown to be dysregulated in virus-related cancers; however, miRNA regulation of virus-related cancer development and progression remains poorly understood. Here, we report that miR-148a is repressed by hepatitis B virus (HBV) X protein (HBx) to promote cancer growth and metastasis in a mouse model of hepatocellular carcinoma (HCC). Hematopoietic pre-B cell leukemia transcription factor-interacting protein (HPIP) is an important regulator of cancer cell growth. We used miRNA target prediction programs to identify miR-148a as a regulator of HPIP. Expression of miR-148a in hepatoma cells reduced HPIP expression, leading to repression of AKT and ERK and,subsequent inhibition of mTOR through the AKT/ERK/FOXO4/ATF5 pathway. HBx has been shown to play a critical role in the molecular pathogenesis of HBV-related HCC. We found that HBx suppressed p53-mediated activation of miR-148a. Moreover, expression of miR-148a was downregulated in patients with HBV-related liver cancer and negatively correlated with HPIP, which was upregulated in patients with liver cancer. In cultured cells and a mouse xenograft model, miR-148a reduced the growth, epithelial-to-mesenchymal transition, invasion, and metastasis of HBx-expressing hepatocarcinoma cells through inhibition of HPIP-mediated mTOR signaling. Thus, miR-148a activation or HPIP inhibition may be a useful strategy for cancer treatment.